Peak Bio, Inc. (PKBO)

OTCMKTS: PKBO · Delayed Price · USD
1.32
0.00 (0.00%)
Feb 3, 2023, 10:15 AM EST - Market closed
Market Cap 26.48M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 20.06M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 130
Open 1.32
Previous Close 1.32
Day's Range 1.32 - 1.32
52-Week Range 1.01 - 15.00
Beta n/a
Analysts Buy
Price Target 15.30 (+1,059.09%)
Earnings Date n/a

About PKBO

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 30
Stock Exchange OTCMKTS
Ticker Symbol PKBO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for PKBO stock is "Buy." The 12-month stock price forecast is $15.3, which is an increase of 1,059.09% from the latest price.

Price Target
$15.3
(1,059.09% upside)
Analyst Consensus: Buy
Stock Forecasts

News

What Is Going on With Peak Bio (PKBO) Stock Today?

It has been a bumpy week and this Friday isn't any easier following the monthly jobs report. However, that doesn't seem to matter for Peak Bio (NASDAQ: PKBO), which recently combined in a deal with I...

3 months ago - InvestorPlace

Peak Bio, Inc. Announces Closing of up to $100 Million Common Stock Purchase Transaction with White Lion Capital

Peak Bio, Inc. ("Peak Bio" or the "Company") (NASDAQ: PKBO), a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory dis...

3 months ago - Business Wire

Peak Bio Co., Ltd. to List on NASDAQ Following Successful Business Combination with Ignyte Acquisition Corp.

NEW YORK--(BUSINESS WIRE)--Peak Bio Co., Ltd.

3 months ago - Business Wire